---
canonical_url: https://www.stockexpertai.com/zh/earnings/unh
last_updated: 2026-05-03T20:47:28.054Z
---

# UnitedHealth Group Incorporated (UNH) Q1 FY2027 财报预览

> 此内容由 FMP 实时数据 + Q1 FY2026 财报电话会议记录自动生成。生成时间：2026-05-03T20:47:27.142Z。本工具为教育目的，不构成投资建议。

---

## 快速摘要

| 字段 | 值 | 来源 |
|---|---|---|
| 价格 | $368.78 (▼ -0.46%) | fmp:quote |
| 市值 | $334.7B | fmp:profile |
| 52周区间 | $234.60 – $409.70 | fmp:quote |
| 财报 | 周二 4 8月 | fmp:earnings-history |
| EPS 预期 | $4.83 (+18% YoY) | fmp:earnings-estimate |
| 营收预期 | $110.7B | fmp:earnings-estimate |
| 超预期连胜 | 3/4 | fmp:earnings-history |
| 评级 | B+ (overall 3/5) | fmp:ratings |
| 分析师中位数目标价 | $380 (+3.0% upside) | fmp:price-target-consensus |
| MoonshotScore | 40/100 | derived |
| Council | 3/6 bullish | derived |
| 芒格结论 | 合理估值 | derived |

## UnitedHealth Group Incorporated — Q1 FY2027 预期

Q1 季度共识：营收 <strong data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvgLabel">$110.7B</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvg" title="FMP est">[FMP est]</sup>，EPS <strong data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">$4.83</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg" title="FMP est">[FMP est]</sup>。连续 3 个季度超出预期<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.beatStreakCount" title="FMP earnings">[FMP earnings]</sup>。

## 快速概览

**得分：** B+ · **立场：** HOLD · **Council：** 3/6 · **Moonshot：** 40

= MoonshotScore <strong>40</strong><sup class="cite" data-source="derived" data-field="moonshot.score" title="MoonshotScore">[MoonshotScore]</sup> + Council <strong>3/6</strong><sup class="cite" data-source="derived" data-field="council.bullishCount" title="Council">[Council]</sup>。Form 4: 0 笔交易<sup class="cite" data-source="fmp:insider-trading" data-field="insider.txCount" title="FMP Form 4">[FMP Form 4]</sup>。

## 观察列表 (6个指标)

### 1. Optum Health Margin Improvement

Optum Health 专注于稳步提高 2026 年的利润率，并在 2027 年加速增长。

> "正如我们在过去 3 个季度中分享的那样，我们的工作重点是管理和流程改进，这些改进将稳步提高 Optum Health 2026 年的利润率，并在 2027 年加速增长。"
> — Patrick Conway, Risk Indicator · Q1 FY2026

### 2. Medicaid Margin Outlook

由于持续的高趋势和资金不足，UnitedHealthcare 预计 2026 年 Medicaid 的会员流失和负利润率，但预计从 2027 年开始利润率将略有改善。

> "鉴于持续的高趋势和资金不足，我们继续预计 2026 年的会员流失和负利润率，并从 2027 年开始略有改善。"
> — Timothy Noel, Expectation / Guide · Q1 FY2026

### 3. Margin Recovery Focus

UnitedHealthcare 优先考虑 2026 年的利润率恢复和产品稳定性，并有意权衡会员增长，尤其是在 Medicare 和商业市场。

> "我们 2026 年的方法优先考虑利润率恢复和产品稳定性，并有意权衡会员增长，尤其是在 Medicare 和商业市场。"
> — Timothy Noel, Risk Indicator · Q1 FY2026

### 4. Ai Driven Efficiency Optum Insight

Optum Insight 的新型 AI 优先产品继续获得青睐，Optum Real 帮助付款人和护理提供者更有效地处理理赔裁决和承保验证等管理职能，并可将人工联系成本降低 76%。

> "Optum Real 正在帮助付款人和护理提供者更有效地处理理赔裁决和承保验证等管理职能，并可将人工联系成本降低 76%。"
> — Patrick Conway, Investor Focus · Q1 FY2026

### 5. Prior Authorization Improvements

UnitedHealthcare 正在努力改进预先授权流程，目前约 50% 的请求可以实时处理，平均超过 90% 的请求可以在 1 个工作日内获得批准。

> "其中约 50% 是实时处理的，平均超过 90% 的请求会在 1 个工作日内获得批准。"
> — Timothy Noel, Investor Focus · Q1 FY2026

### 6. Aca Membership Decline

UnitedHealthcare 仍然预计 2026 年会员总数将下降约 1/3。

> "我们仍然预计 2026 年会员总数将下降约 1/3。"
> — Timothy Noel, Investor Focus · Q1 FY2026


## MoonshotScore 支柱

| 支柱 | 得分 | 水平 | 证据 |
|---|---|---|---|
| 营收增长 | 0.0 | weak | Q1 vs Q2: 增长放缓 (+%0.1，低于阈值) |
| 毛利率 | 2.0 | weak | Q1: 低毛利率 (%22.7，资本密集型或大宗商品) |
| 经营杠杆 | 1.0 | weak | 营业利润率平均 (%8.0) |
| 现金流储备 | 10.0 | strong | FCF 非常强劲 ($8.1B，是资本支出的 10.7 倍以上) |
| 研发投入强度 | 3.0 | weak | 低研发投资 (%0.0，创新薄弱) |
| 价格动能 | 4.0 | medium | RSI 82.7 超买，50日均线 之上 |
| 新闻情绪 | 8.0 | strong | 强烈买入共识 (82%) |

**公式:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula.

## Council (7视角)

| 名称 | 立场 | 背景 |
|---|---|---|
| Ray Dalio | bull | 宏观 · 目标上涨空间 +3.0% |
| Ken Griffin | bull | 资金流 · 50日均线 之上 |
| Jim Simons | bear | 量化 · RSI 83 |
| Klarman | neutral | 价值 · 目标上涨空间 +3.0% |
| Buffett | bull | 质量 · ROE 评分 4/5 |
| Munger | neutral | 估值 · 目标上涨空间 +3.0% |

**公式:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr.

## 芒格视角

- **结论:** 合理估值
- **财务健康:** Moderate
- **安全边际:** Weak
- **利息覆盖率:** Adequate
- **ROIC vs WACC:** Healthy

**公式:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget.

## 技术水平

- **RSI(14):** 82.7 — overbought (RSI 82.7) — geri çekilme baskısı
- **50日均线:** $301 — hisse %22.4 üstünde — kısa vadeli destek
- **200日均线:** $315 — hisse %16.9 üstünde — uzun vadeli destek
- **成交量 (10日):** -51%

## 历史表现 (4个季度)

| 季度 | 实际 EPS | 预期 EPS | 结果 | 反应 |
|---|---|---|---|---|
| Q2 FY25 | $4.08 | $4.45 | MISS | +1.9% |
| Q3 FY25 | $2.92 | $2.80 | BEAT | -3.4% |
| Q4 FY25 | $2.11 | $2.10 | BEAT | +4.0% |
| Q1 FY26 | $7.23 | $6.58 | +9.9% EPS | +2.2% |

Q1 (2026年4月21日): EPS $7.23 vs 预期 $6.58<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>，超出 +%9.9。D+1 走势：+2.2%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP D+1">[FMP D+1]</sup>。尽管超出预期，但股价下跌 — 市场对指引而非数据做出反应。

## 3种情景

### 情景 A · 超预期
**Q1 EPS > $4.83 + 资本支出纪律**

阈值：EPS > $4.83<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>。

目标：突破中位数目标价 $380<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP target]</sup>；高目标价 $444<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.high">[FMP]</sup> 为上限。

### 情景 B · 符合预期
**EPS ≈ $4.83 + CapEx < $763.0M**

阈值：EPS ≈ $4.83<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>，Q1 资本支出 < $763.0M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel">[FMP]</sup>。

目标：在当前价 $369<sup class="cite" data-source="fmp:quote" data-field="quote.price">[FMP]</sup> 与中位数目标价 $380<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP]</sup> 区间内盘整。

### 情景 C · 未达预期
**EPS < $4.69 或 CapEx ≥ $763.0M**

阈值：EPS < $4.69<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est×0.97]</sup>。

目标：当前价 $369 低于 200日均线 $315<sup class="cite" data-source="fmp:technical" data-field="technical.sma200">[FMP]</sup>，若持续拒绝，则激活 $268<sup class="cite" data-source="derived" data-field="technical.sma200" data-formula="round(sma200*0.85)">[derived]</sup> 支撑位。

## 风险提示

### {{segment}} 低于阈值
Q1 季度：EPS $7.23 vs 预期 $6.58<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>，超出预期，股价 D+1 +2.2%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP">[FMP]</sup>。

### 对 OpenAI 的依赖
Q1 财报电话会议中未披露 RPO/积压集中度。

### 内幕交易
Form 4 数据已在表格中标记 — 本页面不为此股票生成假设。

| 高管 | 操作 | 金额 | 日期 |
|---|---|---|---|


**净额:** — (0 笔交易 · 0 笔卖出 · 0 笔买入) · Q1 FY26

### 资本支出冲击
Q1 季度资本支出 $763.0M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel" title="FMP cashflow">[FMP cashflow]</sup>。 Q1 营业利润率 %8.0<sup class="cite" data-source="fmp:income" data-field="income.quarters.0.operatingMargin" title="FMP op margin">[FMP op margin]</sup> — Q1 的这一水平对资本支出修订风险敏感。

## 华尔街共识

- **中位数目标价:** $380 (+3.0% upside vs current $369)
- **高 / 低:** $444 / $327
- **买入 / 持有 / 卖出:** 23 / 4 / 1
- **分析师数量:** 2 (上一季度), 104 历史总数

## 额外财报电话会议洞察

### 1. margin_recovery_focus

**主张:** UnitedHealthcare is prioritizing margin recovery and product stability in 2026, with a deliberate trade-off on membership growth, particularly in Medicare and commercial markets.

**证据 (会议记录):** "Our 2026 approach prioritizes margin recovery and product stability with a deliberate trade-off on membership growth, particularly in Medicare and commercial markets."

**数据:** 2026

### 2. medicaid_margin_outlook

**主张:** UnitedHealthcare expects membership attrition and negative margins in Medicaid in 2026 due to continuing high trend and insufficient funding, with modest margin improvements beginning in 2027.

**证据 (会议记录):** "We continue to expect membership attrition and negative margins in 2026 in light of continuing high trend and insufficient funding with modest margin improvements beginning in 2027."

**数据:** 2026, 2027

### 3. aca_membership_decline

**主张:** UnitedHealthcare still expects total membership to decline by approximately 1/3 in 2026.

**证据 (会议记录):** "We still expect total membership to decline by approximately 1/3 in 2026."

**数据:** 1/3, 2026

### 4. prior_authorization_improvements

**主张:** UnitedHealthcare is working to improve prior authorization processes, with about 50% of requests now processed in real time, and more than 90% approved on average in 1 business day.

**证据 (会议记录):** "About 50% of those are processed in real time, and more than 90% are approved on average in 1 business day."

**数据:** 50%, 90%, 1

### 5. optum_health_margin_improvement

**主张:** Optum Health is focused on steadily improving margins for 2026 and accelerating into 2027.

**证据 (会议记录):** "As we have shared over the past 3 quarters, our efforts are focused on management and process improvements that steadily improve margins at Optum Health for 2026 and accelerate into 2027."

**数据:** 3, 2026, 2027

### 6. ai_driven_efficiency_optum_insight

**主张:** Optum Insight's new AI-first products continue to gain traction, with Optum Real helping payers and care providers deal more efficiently with administrative functions such as claim adjudication and coverage validation and can reduce manual contact costs by 76%.

**证据 (会议记录):** "Optum Real is helping payers and care providers deal more efficiently with administrative functions such as claim adjudication and coverage validation and can reduce manual contact costs by 76%."

**数据:** 76%


---

*数据来源：FMP (实时查询，2026-05-03)，Q1 FY2026 财报电话会议记录 (由 Gemini 2.0 Flash 翻译成中文)。本工具为教育目的，不构成投资建议。*
